Primary Ciliary Dyskinesia Market Research Report - Forecast till 2027

Primary Ciliary Dyskinesia Market Information: By Diagnosis (Genetic Testing, Electron Microscopy, and other), Treatment (Radiotherapy, Chemotherapy, others), and End User (Hospitals & Clinics, Research Centers, and others) - Forecast till 2027

ID: MRFR/Pharma/3010-HCR | February 2021 | Region: Global | 125 pages         

Primary Ciliary Dyskinesia Market Speak to Analyst Request a Free Sample

Primary Ciliary Dyskinesia Market Scenario


Primary ciliary dyskinesia (PCD), also kown as immotile ciliary syndrome or Kartagener syndrome. Primary ciliary dyskinesia is a rare disorder and is a type of chronic respiratory tract infections, normally occurs in internal organs of human body. The major symptoms of this condition are caused by abnormal cilia and flagella. Normally cilia are microscopic, finger-like projections that stick out from the surface of cells. They are found in the linings of the airway, the reproductive system, and other organs and tissues. Flagella are tail-like structures, similar to cilia that propel sperm cells forward.


In some cases, mutations in the genes can cause primary ciliary dyskinesia result in defective cilia that move abnormally or are unable to move. As cilia have many important functions within the body, defects in these cell structures cause diseased condition


Increasing prevalence of respiratory tract diseases is one of the major factors for the growth of the primary ciliary dyskinesia market during the forecast period. According to the Centers for Disease Control and Prevention (2014), 9.3 million adults diagnosed with respiratory problems. Whereas, 147,101 deaths occurred due to chronic lower respiratory diseases.It is predicted to be the 3rd most death causing factor.


According to the World Health Organization (WHO), over 7 million deaths occur each year of which more than 6 million deaths result from direct use of tobacco. Moreover, According to Eurostat’s, (2014), COPD (Chronic Obstructive Pulmonary Disease) affected more than 200 million people worldwide and is one of the major diseases whose prevalence is increasing across the globe.


However, high cost of the current treatment methods and lack of awareness about rare respiratory diseases such as primary ciliary dyskinesia may hamper the primary ciliary dyskinesia market growth over the review period.


The primary ciliary dyskinesia market is expected to grow at a CAGR of ~6.7% during the forecast period 2017-2023.


Key Players                                                                                                        

Some of the key players in primary ciliary dyskinesia market are AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Novartis AG, Pfizer Inc., Teva UK Limited, Masimo Corporation (U.S.), BD (U.S.), Portex Division of Smith Industries Medical System, Teruma Medical Corporation, HTL STREFA SA, Greinier Bio One International GmBH., F. Hoffman La Roche AG, Bayer AG., Acare Technology Co., Medline Industries Inc., Ltd., Hill-Rom Holdings Inc., Allied Healthcare Inc., Rotech Healthcare Inc., and others. 


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Manufacturer

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Market Segmentation   
                                                                                                                             
The primary ciliary dyskinesia market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of diagnosis, the primary ciliary dyskinesia market is segmented into genetic testing, electron microscopy, and others.


On the basis of treatment, the primary ciliary dyskinesia market is categorized into drug treatment, radiotherapy, chemotherapy, others. On the basis of drug treatment, it is further segmented into clarithromycin, erythromycin and azithromycin, and others.


On the basis of end user, the primary ciliary dyskinesia market is segmented into hospitals & clinics, research centers, and others.

Figure: Primary Ciliary Dyskinesia Market, by Treatment, 2016 (%)
Primary Ciliary Dyskinesia Market-


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation


Regional Analysis

The Americas dominates the primary ciliary dyskinesia market owing to the presence of strong economic condition, huge development in healthcare domain, and focus of research institutions on updating technology for rare diseases diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the primary ciliary dyskinesia market.


Europe holds the second largest primary ciliary dyskinesia market across the globe due to encouraging government policies for research & development and healthcare professionals by various European countries such as France and Germany. Moreover, according to Eurostat’s, (2014), over 401000 deaths were caused by respiratory system diseases, which are equivalent to 8.0 % of all deaths. Proportion of deaths in the UK from respiratory diseases is considerably higher than the other European countries, which will drive the market growth in this region during the forecast period.  


Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India, china are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from respiratory diseases in developing countries will directly increase the demand for various treatment methods and will boost the growth of the primary ciliary dyskinesia market.    


The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more in healthcare domain and developing medical facilities, which will boost the primary ciliary dyskinesia market growth in this region.


Research Methodology
Primary Ciliary Dyskinesia Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.7% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Novartis AG, Pfizer Inc., Teva UK Limited, Masimo Corporation (U.S.), BD (U.S.), Portex Division of Smith Industries Medical System, Teruma Medical Corporation, HTL STREFA SA, Greinier Bio One International GmBH., F. Hoffman La Roche AG, Bayer AG., Acare Technology Co., Medline Industries Inc., Ltd., Hill-Rom Holdings Inc., Allied Healthcare Inc., Rotech Healthcare Inc., and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Increasing prevalence of respiratory tract diseases


Speak to Analyst Ask for Customization